Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azithromycin plus chloroquine versus artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria
2014-004163-21Phase 3
- Sponsor
- Pfizer
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of azithromycin, chloroquine, artemether and lumefantrine in Malaria (2 arms), sponsored by Pfizer. Primary endpoint: Percentage of subjects with PCR-corrected adequate clinical and parasitologic response at Day 28.
02
Drugs
azithromycinchloroquineartemetherlumefantrine
03
Conditions
Malaria
Beyond the preview
Go deeper on 2014-004163-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004163-21.